In Brief: Ventritex
This article was originally published in The Gray Sheet
Executive Summary
Ventritex: Begins U.S. clinical trials of its SPL single-wire transvenous lead system following receipt of an investigational device exemption from FDA. The SPL incorporates technology from Ventritex' dual-lead TVL transvenous lead, which was approved by FDA in May ("The Gray Sheet" May 20, I&W-1). An initial U.S. implant of the SPL was performed May 28 at St. Vincent Hospital in Indianapolis, Ventritex says...